INSM Stock Price Today (July 2026) — INSM Analysis & Key Metrics 2026-07-17
INSM (INSM) is trading at $108.32, up 0.80% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Software growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $197.05 (81.9% upside).
- Volatility remains elevated (32.57% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.30% YoY) alongside significant competitive pressures.
INSM Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
INSM - Historical Price & Volume
Market Cap
Enterprise Value: $23.71B
P/E Ratio
Forward P/E: 807.58
Revenue Growth
Year over Year
Analyst Target
+81.9% upside potential
Key Investor Questions About INSM
What investors need to know before buying
Based on current market data, INSM presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 48.40)
- Fundamentals say: Caution warranted (high leverage concerns)
INSM's growth trajectory depends on its ability to expand within the Software sector while managing margin pressures.
- Future growth will depend on performance in core Software operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for INSM investors include debt exposure and competitive dynamics in the Software industry.
- $742.46M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Software.
52-Week Trading Range
Over the past year, INSM stock traded between $90.39 and $212.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.57% annualized volatility and β=0.70, the stock exhibits low sensitivity to market moves—making INSM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study
Insmed (NASDAQ:INSM) reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures and a generally favorable safety profile over longer-term use. TPIP is an inhaled prodrug of trepros
Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside […]
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks. On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company’s first-quarter report. Mizuho found […]
Nebius and CoreWeave fall after Nasdaq 100 listing
Nabius and CoreWeave surged in the lead up to their Nasdaq 100 listing, but have fallen in the to days since their inclusions.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors?
Insmed Incorporated was removed from the NASDAQ-100 Index on 19 June 2026, even as investor focus intensified on its experimental lung drug TPIP. Analyst commentary now emphasizes TPIP’s upcoming clinical data as a potential turning point for Insmed’s rare respiratory disease portfolio and overall outlook. We’ll now examine how heightened expectations around TPIP’s upcoming data release may reshape Insmed’s existing clinical and earnings narrative. We've uncovered the 7 dividend fortresses...
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise?
Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235. The firm pointed to an upcoming data release for Insmed’s experimental lung drug TPIP as a potential […]
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.
Nasdaq-100 Onboards 5 New Stocks in AI-Fueled Rebalancing
This morning, the Nasdaq-100 is getting its quarterly rebalance with five firms getting the boot and five taking their place.
Frequently Asked Questions
Common investor questions about INSM
INSM (INSM) is currently trading at $108.32. The RSI (14-day) is at 48.4, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $197.05 implies 81.9% upside from current levels. Volatility is moderate at 32.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for INSM (INSM): The trailing P/E ratio is -18.81, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 807.58. Price-to-Book is 33.28. Price-to-Sales is 28.65. Valuation should be compared to Software industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering INSM, the consensus price target is $197.05. This represents a 81.9% upside from the current price of $108.32. The range spans from a low target of $140.00 to a high target of $243.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
INSM (INSM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for INSM (INSM) investors include: 1. Moderate volatility (32.6% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 105.34) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Software sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is INSM's (INSM) current debt and financial health profile: Total debt stands at $742.46M. The debt-to-equity ratio is 105.34, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 4.47, indicating strong short-term liquidity. The quick ratio is 3.88. The company holds $1.22B in cash and equivalents. Free cash flow is negative at $-606,202,112, which could limit the company's ability to manage debt obligations.